AstraZeneca stock price forecast: GBX13,955 support in focus as AZN holds steady

Traders Union
All News
Financial News
AstraZeneca slips 0.06% to GBX14,286 today

Highlights

AstraZeneca and Daiichi Sankyo secured EU approval for Enhertu as the first tumour-agnostic oncology therapy, enabling immediate European market entry.
Phase III trials for efzimfotase alfa in hypophosphatasia demonstrated statistically significant efficacy and favorable safety, enhancing regulatory and adoption prospects.
AZN trades in a bullish technical setup, with strong momentum and 79% probability of remaining within the GBX13,533 to GBX15,038 range, but overbought signals caution for short-term pullbacks.

Oncology expansion accelerates as regulatory wins drive sentiment

AstraZeneca and Daiichi Sankyo have received European Commission approval for Enhertu as the first tumour-agnostic treatment, paving the way for immediate market entry and expanding the company’s presence in innovative oncology therapies, according to Tipranks. Clinical trial updates remained positive, as MULBERRY Phase III data demonstrated statistically significant and clinically meaningful benefits for efzimfotase alfa, also noted by Tipranks. A favourable safety profile from Phase III hypophosphatasia trials was reported for efzimfotase alfa, which addresses regulatory and adoption considerations, according to Tradingview. Additionally, AstraZeneca’s transition from Nasdaq to NYSE in early February 2026, as reported by Financial News Co, is positioned to broaden its shareholder base and support future liquidity.

Overbought momentum persists as buyers test technical boundaries

AZN is trading above the MA-20 at GBX14,021 and the MA-50 at GBX13,690 on the hourly timeframe, and also above the MA-200 at GBX13,658 on the daily chart. The Ichimoku Kijun level at GBX13,955 acts as immediate support. Momentum indicators like the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both remain in Buy mode. However, the Relative Strength Index (RSI), Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power all reflect overbought conditions, suggesting buyer dominance in recent sessions. The Awesome Oscillator also aligns with the positive trend, but intraday price action posted a modest decline and closed near the session low, highlighting a risk of short-term pullback or sideways movement.

Volatility band guides outlook as upside probability outweighs risks

Over the next 2 to 3 trading days, AZN is expected to fluctuate within the GBX13,533 to GBX15,038 volatility band relative to current levels. There is a 79% probability of further upside, while a downward move has a 21% likelihood. The baseline scenario is for the price to remain within this projected range. Should the price break above resistance, a move toward the upper end of the range is expected, but a drop below immediate support could prompt a decline toward the lower boundary.

Viktoras Karapetjanc, expert at Traders Union, sees AstraZeneca supported by strong regulatory wins and robust clinical trial results. He notes that European approval for Enhertu and positive Phase III data strengthen both sentiment and the company’s long-term fundamentals. Despite a modest daily dip, the technical setup remains constructive above key moving averages. The upcoming NYSE listing is likely to broaden investor participation. "With regulatory momentum and expanding institutional interest, I expect AstraZeneca to stay resilient and maintain its upward trajectory in the coming sessions."

Previously it was reported that major government investment in Cambridge South station is set to strengthen access to the region’s leading science and healthcare hubs, directly benefiting companies like AstraZeneca. With the stock maintaining key technical momentum amid positive regulatory and clinical updates, investors should watch for potential volatility if support at GBX13,955 fails, which could test lower bands in the days ahead.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.